Evidence map›Paper›PMID 26037048›Full record

ReviewCurrent topics in microbiology and immunology2016

The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.

Frank Cichocki, Michael R Verneris, Sarah Cooley, Veronika Bachanova, Claudio G Brunstein, Bruce R Blazar, John Wagner, Heinrich Schlums, Yenan T Bryceson, Daniel J Weisdorf and 1 more

Abstract readHistorical ArticleReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current topics in microbiology and immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Frank CichockiDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Michael R VernerisDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Sarah CooleyDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Veronika BachanovaDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Claudio G BrunsteinDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Bruce R BlazarDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
John WagnerDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Heinrich SchlumsCentre for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Yenan T BrycesonCentre for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Daniel J WeisdorfDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Jeffrey S MillerDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA. mille011@umn.edu.

Funding

Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
Viral priming and targeting NK cells against solid tumor malignanciesR35CA197292 · NCI · UNIVERSITY OF MINNESOTA · PI MILLER, JEFFREY S. · 2015 to 2021
$6.2M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)KL2TR000113 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$5.4M
GVL TO REDUCE AML RELAPSE AFTER MURINE ALLOGENEIC BMTR01CA072669 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1997 to 2017
$4.9M
Molecular Programming of Immunological Memory in Human Natural Killer CellsK99HL123638 · NHLBI · UNIVERSITY OF MINNESOTA · PI CICHOCKI, FRANK · 2015 to 2016
$190k
NCATS NIH HHS KL2 TR000113NCATS NIH HHS UL1 TR000114NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS P01 CA655493NCI NIH HHS R01 CA072669NCI NIH HHS R01CA72669NCI NIH HHS R35 CA197292NHLBI NIH HHS K99 HL123638
6 · The paper itself

Abstract

Hematopoietic cell transplantation (HCT) has been used as a part of cancer therapy for over half a decade. Beyond the necessity for donor-derived cells to reconstitute hematopoiesis after radiation and chemotherapy, immunologic reconstitution from allogeneic cells is important for the elimination of residual tumor cells. Natural killer (NK) cells are first among lymphocytes to reconstitute post-transplant and protect against cancer relapse. In this review, we provide a historical perspective on the role of NK cells in cancer control in the transplant setting and focus on current research aimed at improving NK cell responses for therapeutic benefit.

Indexed as

Adoptive TransferAnimalsHematopoietic Stem Cell TransplantationHistory, 20th CenturyHistory, 21st CenturyHumansImmunotherapy, AdoptiveKiller Cells, Natural

Identifiers

PMID26037048
PMCPMC5870762

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.